Nachrichten zur Regeneron Pharmaceuticals Aktie

Form 8-K REGENERON PHARMACEUTICAL For: Feb 03

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron Pharmaceuticals Q4 Profit Declines

WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) released earnings for fourth quarter that decreased from last yearThe companys earnings came in…

UPDATE 1-Regeneron quarterly profit plunges as COVID drug sales dry up

...(Adds quarter details, background) Feb 3 (Reuters) - Regeneron......…

Regeneron stock rallies after profit and revenue beat expectations by wide margins

Shares of Regeneron Pharmaceuticals Inc. REGN rallied 1.9% toward a two-month high in premarket trading Friday, after the biotechnology company…

CORRECTED-Regeneron quarterly profit drops 46%

... in paragraph 2) Feb 3 (Reuters) - Regeneron Pharmaceuticals Inc reported......…

Regeneron quarterly profit drops 46%

...(Reuters) - Regeneron Pharmaceuticals Inc reported an about 46......…

Regeneron Pharmaceuticals reports Q4 earnings beat; initiates FY23 guidance

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

TARRYTOWN, N.Y., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for…

DAX: US-Arbeitsmarktdaten am Nachmittag, Sanofi, Regeneron, ThyssenKrupp, Verbio, Apple, Amazon und Alphabet im Fokus – das ist heute wichtig

Nach der Vortagesrally dürften es die Anleger am Freitag am deutschen Aktienmarkt zunächst langsamer angehen lassen. Der Broker IG taxierte…

Time to Buy Cigna or Regeneron Stock Before Earnings?

Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and…

Regeneron (REGN) Stock Moves -0.86%: What You Should Know

Regeneron (REGN) closed the most recent trading day at $736.46, moving -0.86% from the previous trading session....…

Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 747$

Brown, Michael S. - Aufsichtsrat - Tag der Transaktion: 2023-01-27...…

Regeneron upgraded at Cowen on potential of high dose Eylea

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sanofi, Regeneron Dupixent gets approval in EU for expanded use in eosinophilic esophagitis

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for…

Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…

Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent

PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced the European Medicines Agencys Committee for Medicinal Products for Human…

Sanofi, Regeneron Dupixent gets EMA panel nod to treat eczema in kids under 5

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sanofi/Regeneron: Dupixent wins new stage of EU regulatory approval

...PARIS, Jan 27 (Reuters) - Healthcare companies Sanofi and Regeneron......…

Decibel, Regeneron get UK regulator nod to start trial of hearing loss gene therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron (REGN) Gains But Lags Market: What You Should Know

Regeneron (REGN) closed the most recent trading day at $729.91, moving +1.1% from the previous trading session....…

Regeneron Pharmaceuticals: Hochstufung

New York (www.aktiencheck.de) - Rating-Update: Chris Schott, Analyst von J.P. Morgan Securities, stuft die Aktie von Regeneron Pharmaceuticals (ISIN: US75886F1075, WKN:…

Regeneron upgraded at JPMorgan on upcoming catalysts

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Annexin appoints Dr. Alain Thibault as Therapeutic Area Head of Oncology.

STOCKHOLM January 18, 2023 Annexin Pharmaceuticals AB (publ) announces that Dr. Thibault, a medical oncologist with extensive global experience leading…

Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know

Regeneron (REGN) closed the most recent trading day at $714.57, moving +0.65% from the previous trading session....…

Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More

Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week....…

Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 2.293.720$

Brown, Michael S. - Aufsichtsrat - Tag der Transaktion: 2023-01-06...…

Regeneron Pharmaceuticals: Kaufempfehlung bestätigt

Minneapolis (www.aktiencheck.de) - Rating-Update: Christopher Raymond, Analyst von Piper Sandler, stuft die Aktie von Regeneron Pharmaceuticals (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol:…

Regeneron slips after $0.21 per share impact to Q4 2022 earnings

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron Stock Sinks on Disappointing Sales of Eylea Vaccine

Eylea, which is injected into the eye, is meant to treat conditions such as macular degeneration, macular edema, and diabetic retinopathy....…

2seventy Bio, Regeneron in Amended Collaboration >TSVT REGN

2seventy Bio, Regeneron in Amended Collaboration >TSVT REGN...…

Insiderhandel: EVP Commercial verkauft Aktien von Regeneron Pharmaceuticals im Wert von 794.046$

Mccourt, Marion - Vorstand - Tag der Transaktion: 2023-01-03...…

Sensei Biotherapeutics Enters Clinical Supply Agreement With Regeneron For Libtayo

WASHINGTON (dpa-AFX) - Sensei Biotherapeutics, Inc. (SNSE) announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo. The…

Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors

BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the…

Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023

TARRYTOWN, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will…

Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 4.111.822$

Coles, N Anthony - Aufsichtsrat - Tag der Transaktion: 2022-12-28...…

Regeneron Granted Marketing Authorization For Libtayo In Japan For Recurrent Cervical Cancer

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced the Ministry of Health, Labor and Welfare in Japan has granted marketing and…

Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer

TARRYTOWN, N.Y., Dec. 23, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) today announced that the Ministry of Health, Labor and…

Regeneron: Positive Dupixent Phase 3 Results In Eosinophilic Esophagitis Published

PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said that the New England Journal of Medicine has published results…

Form 8-K REGENERON PHARMACEUTICAL For: Dec 19

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y., Dec. 19, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 41st Annual…

Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis

The CHMP recommends approval of Sanofi (SNY) and partner Regenerons Dupixent for the treatment of adults and adolescents with eosinophilic…

Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop

WALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a…

dpa-AFX ProFeed